|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:doxorubicin
|
|
gptkbp:activities
|
produces free radicals
intercalates DNA
inhibits RNA synthesis
|
|
gptkbp:appointed_by
|
injection
|
|
gptkbp:approves
|
gptkb:1974
gptkb:FDA
|
|
gptkbp:associated_with
|
cardiotoxicity
secondary malignancies
myelosuppression
extravasation injury
|
|
gptkbp:brand
|
gptkb:Doxorubicin
|
|
gptkbp:can_be_used_with
|
gptkb:paclitaxel
gptkb:cisplatin
gptkb:cyclophosphamide
|
|
gptkbp:class
|
anthracycline
|
|
gptkbp:clinical_trial
|
Phase IV
Phase II
Phase III
Phase I
|
|
gptkbp:contraindication
|
pregnancy
severe liver disease
|
|
gptkbp:developed_by
|
Streptomyces peucetius
|
|
gptkbp:discovered_by
|
David L. Longo
|
|
gptkbp:established
|
topoisomerase II
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Adriamycin
|
|
gptkbp:ingredients
|
C27 H29 N O11
|
|
gptkbp:interacts_with
|
gptkb:cyclosporine
gptkb:trastuzumab
gptkb:warfarin
|
|
gptkbp:is_available_in
|
vials
infusion bags
|
|
gptkbp:is_available_on
|
generic drug
|
|
gptkbp:is_used_for
|
gptkb:healthcare_organization
gptkb:neuroblastoma
ovarian cancer
stomach cancer
esophageal cancer
bladder cancer
head and neck cancer
treating cancer
|
|
gptkbp:lifespan
|
20-48 hours
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:side_effect
|
nausea
hair loss
heart damage
|
|
gptkbp:storage
|
room temperature
protected from light
|
|
gptkbp:targets
|
gptkb:DJ
|